Regeneron PharmaceuticalsREGN

• Phase 3피안리맙·세미플리맙 흑색종 수술 후 재발 방지 비교 임상진행 중A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
  48%
• Phase 3오드로넥스타맙 여포성 림프종 병용요법 3상진행 중A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
  59%
• Phase 3기존 치료 불응 혈색소뇨증 대상 신약 병용 임상모집 중A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
  47%
• Phase 3희귀 혈액질환 PNH 환자 대상 포젤리맙 복합제 장기 치료 임상모집 중A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
  47%
• Phase 1황반변성 지도모양위축 안구 내 포젤리맙 주사 치료 임상모집 중Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
  48%
• Phase 3여포성 림프종 오드로넥스타맙 병용 비교 임상모집 중A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
  59%
• Phase 1신규 다발골수종 환자 대상 Linvoseltamab 초기 치료 임상모집 중A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
  62%
• Phase 3린보셀타맙 재발·불응성 다발골수종 비교 3상 임상모집 중A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
  60%
• Phase 1린보셀타맙 재발·불응성 다발골수종 1/2상모집 중Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
  62%
• Phase 3린보셀타맙 vs 다라투무맙 다발골수종 전단계 치료 비교시작 전A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
  59%
• Phase 2린보-VR 대 DVRd 다발성 골수종 1차 치료 비교 임상시작 전A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)
  47%
• Phase 3발작성 야간 혈색소뇨증 포젤리맙·셈디시란 병용 임상모집 중A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
  74%

성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.